Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
US FDA authorizes early access to Revolution's pancreatic cancer pill
12:54pm, Friday, 01'st May 2026
The U.S. Food and Drug Administration has authorized the granting of early access before regulatory approval to Revolution Medicines' pill for patients with previously treated pancreatic cancer,
Which Is the Better Small-Cap ETF, Vanguard's VB or iShares' ISCB?
09:06am, Friday, 01'st May 2026
Compare how sector allocations, cost, and diversification set these two leading small-cap ETFs apart for investors seeking broad market exposure.
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
04:05pm, Wednesday, 29'th Apr 2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
Vanguard vs. Schwab: Which Small-Cap ETF Belongs in Your Portfolio?
01:08pm, Wednesday, 29'th Apr 2026
Expense ratios, diversification, and recent returns reveal key differences between these two leading small-cap ETFs.
Schwab Small Cap ETF Tops State Street in Returns and Diversification
11:27am, Wednesday, 29'th Apr 2026
Compare how expense ratios, yield, and portfolio breadth set these two small-cap ETFs apart in risk and income profile.
There's a Revolution in Cancer. But Can Big Pharma Afford It?
05:30am, Tuesday, 28'th Apr 2026
Revolution Medicines' stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.
Investors have grown excited about Revolution Medicines due to its promising pancreatic cancer drug, daraxonrasib. Daraxonrasib significantly extended the life of patients in a recent clinical trial.
SPSM Offers Lower Costs and Higher Yield Than ISCB
10:50am, Friday, 24'th Apr 2026
Explore how these two small-cap ETFs differ in diversification, risk, and portfolio strategy to help refine your investment approach.
Two experimental drugs showed striking early results against pancreatic cancer
05:35pm, Tuesday, 21'st Apr 2026
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colore
REDWOOD CITY, Calif. , April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
Mark Goldsmith Sells 120,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
04:05am, Sunday, 19'th Apr 2026
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Mark Goldsmith sold 120,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an av
